KR20240144440A - 인간에게 투여하기 위해 제제화된 항-cd28 인간화 항체 - Google Patents

인간에게 투여하기 위해 제제화된 항-cd28 인간화 항체 Download PDF

Info

Publication number
KR20240144440A
KR20240144440A KR1020247030946A KR20247030946A KR20240144440A KR 20240144440 A KR20240144440 A KR 20240144440A KR 1020247030946 A KR1020247030946 A KR 1020247030946A KR 20247030946 A KR20247030946 A KR 20247030946A KR 20240144440 A KR20240144440 A KR 20240144440A
Authority
KR
South Korea
Prior art keywords
dose
weeks
once
subjects
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247030946A
Other languages
English (en)
Korean (ko)
Inventor
베르나르드 반호브
Original Assignee
오제 이뮈노테라프틱스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오제 이뮈노테라프틱스 filed Critical 오제 이뮈노테라프틱스
Publication of KR20240144440A publication Critical patent/KR20240144440A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
KR1020247030946A 2015-12-15 2016-12-15 인간에게 투여하기 위해 제제화된 항-cd28 인간화 항체 Pending KR20240144440A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP15200281.2 2015-12-15
EP15200281 2015-12-15
EP16306537.8 2016-11-22
EP16306537 2016-11-22
PCT/EP2016/081286 WO2017103003A1 (en) 2015-12-15 2016-12-15 Anti-cd28 humanized antibodies formulated for administration to humans
KR1020187020218A KR20180087428A (ko) 2015-12-15 2016-12-15 인간에게 투여하기 위해 제제화된 항-cd28 인간화 항체

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187020218A Division KR20180087428A (ko) 2015-12-15 2016-12-15 인간에게 투여하기 위해 제제화된 항-cd28 인간화 항체

Publications (1)

Publication Number Publication Date
KR20240144440A true KR20240144440A (ko) 2024-10-02

Family

ID=57737702

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247030946A Pending KR20240144440A (ko) 2015-12-15 2016-12-15 인간에게 투여하기 위해 제제화된 항-cd28 인간화 항체
KR1020187020218A Ceased KR20180087428A (ko) 2015-12-15 2016-12-15 인간에게 투여하기 위해 제제화된 항-cd28 인간화 항체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187020218A Ceased KR20180087428A (ko) 2015-12-15 2016-12-15 인간에게 투여하기 위해 제제화된 항-cd28 인간화 항체

Country Status (16)

Country Link
US (4) US20180215824A1 (https=)
EP (2) EP3390450B1 (https=)
JP (1) JP6923528B2 (https=)
KR (2) KR20240144440A (https=)
CN (1) CN108699148A (https=)
CY (1) CY1124141T1 (https=)
DK (1) DK3390450T3 (https=)
ES (1) ES2862395T3 (https=)
HR (1) HRP20210445T1 (https=)
HU (1) HUE053736T2 (https=)
LT (1) LT3390450T (https=)
PL (1) PL3390450T3 (https=)
RS (1) RS61958B1 (https=)
SI (1) SI3390450T1 (https=)
SM (1) SMT202100185T1 (https=)
WO (1) WO2017103003A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2536764B1 (en) * 2010-02-18 2018-07-04 OSE Immunotherapeutics Anti-cd28 humanized antibodies
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
JP2024531915A (ja) 2021-08-05 2024-09-03 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｍｕｃ抗体およびその使用
CA3230934A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
AU2022339819A1 (en) 2021-09-03 2024-04-11 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
CN119110809A (zh) 2022-02-23 2024-12-10 Xencor股份有限公司 抗CD28 x抗PSMA抗体
US20240059786A1 (en) * 2022-02-24 2024-02-22 Xencor, Inc. Anti-cd28 x anti-trop2 antibodies
CA3267921A1 (en) 2022-10-06 2024-04-11 Bicara Therapeutics Inc. MULTISPECIFIC PROTEINS AND ASSOCIATED PROCESSES

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004032969A1 (en) * 2002-10-09 2004-04-22 Lorantis Limited Modulation of immune function
US7651855B2 (en) * 2003-04-17 2010-01-26 The Trustees Of The University Of Pennsylvania Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses
CN100376599C (zh) * 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
US20110097339A1 (en) * 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
EP2536764B1 (en) * 2010-02-18 2018-07-04 OSE Immunotherapeutics Anti-cd28 humanized antibodies
HUE065915T2 (hu) * 2011-03-11 2024-06-28 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antitestek és alkalmazásaik
KR101941004B1 (ko) * 2013-03-25 2019-01-23 주식회사 엘지화학 조절 t 세포로의 분화 유도 및 증식 촉진을 통한 면역 반응 억제용 약학 조성물

Also Published As

Publication number Publication date
PL3390450T3 (pl) 2021-09-13
SMT202100185T1 (it) 2021-05-07
US20250051446A1 (en) 2025-02-13
WO2017103003A1 (en) 2017-06-22
SI3390450T1 (sl) 2021-08-31
US20200115453A1 (en) 2020-04-16
CN108699148A (zh) 2018-10-23
DK3390450T3 (da) 2021-03-01
US20220411510A1 (en) 2022-12-29
EP3390450A1 (en) 2018-10-24
LT3390450T (lt) 2021-06-25
JP6923528B2 (ja) 2021-08-18
RS61958B1 (sr) 2021-07-30
ES2862395T3 (es) 2021-10-07
KR20180087428A (ko) 2018-08-01
US20180215824A1 (en) 2018-08-02
CY1124141T1 (el) 2022-05-27
JP2018538309A (ja) 2018-12-27
HRP20210445T1 (hr) 2021-06-25
EP3390450B1 (en) 2021-01-20
EP3868785A1 (en) 2021-08-25
HUE053736T2 (hu) 2021-07-28

Similar Documents

Publication Publication Date Title
US20220411510A1 (en) Anti-CD28 Humanized Antibodies Formulated for Administration to Humans
KR102306366B1 (ko) Cd127에 대해 지시된 항체 및 폴리펩타이드
JP7284557B2 (ja) 医薬組成物
JP6861301B2 (ja) 移植片拒絶の予防に使用するための抗ｃｄ４０抗体
US12286483B2 (en) Method of treating cancer using CD137 antibodies and PD-1 antagonists
JP2022116272A (ja) Ｔ１ｄｍ及び膵島炎の治療に使用するための抗ｃｄ４０抗体
KR20170052526A (ko) 다발성 경화증에 대한 병용 치료
KR20220034029A (ko) 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN113272017A (zh) 抗tim-3抗体
US20230181732A1 (en) Combinations of immunotherapies and uses thereof
JP2024538755A (ja) がんを処置するための、抗ｐｄ－１抗体との組合せにおけるｐｄ－ｌ１及びｃｄ１３７に対する多特異性結合剤
HK40058111A (en) Anti-cd28 humanized antibodies formulated for administration to humans
KR20230154239A (ko) 항체-매개 이식 거부의 치료에 사용하기 위한 항-cd38 항체
HK1260979B (en) Anti-cd28 humanized antibodies formulated for administration to humans
HK1260979A1 (en) Anti-cd28 humanized antibodies formulated for administration to humans
Jarvi Mechanism-Based Approaches to Predict and Mitigate the Immunogenicity Challenges of Biological Modalities
TW202506731A (zh) 治療多重抗藥性細菌感染之方法
CN116997570A (zh) 用于治疗抗体介导的移植排斥的抗cd38抗体
HK40058527A (en) Anti-tim-3 antibodies
EA046914B1 (ru) Антитела-агонисты, которые связывают cd137 человека, и варианты их применения

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240913

Application number text: 1020187020218

Filing date: 20180713

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241011

Comment text: Request for Examination of Application